SarcopeniaNCT03121326
The Study of Sarcopenia and Aging Biomarkers by the Metabolomics
An observational study of Sarcopenia and Aging, run by Chang Gung Memorial Hospital at 1 site in Taiwan.
Trial summary
With the rapid growth of the global elderly population, the studies of the biomarkers of the sarcopenia and aging are under investigation in different ways. The investigators use Metabolomics to explore the biomarkers of the sarcopenia and aging of the senior adults. Read more about this study
- Who is it for?
- Ages 60 years and olderHealthy volunteers can take part
- Conditions the study is for
- Sarcopenia, Aging
- What is being tested?
- blood and urine sampling
- How many people
- 650 participants
- Where
- 1 siteTaiwan
- Study dates
- 6 Mar 2017to 31 Dec 2017
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 60 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: 650 residents of the Chang Gung Health and Culture Village aged over 60.
Who may be able to join
- residents of the Chang Gung Health and Culture Village
- mostly independent and do not require nursing assistance
- capable of managing their daily living activities
- aged ≧ 60
Who cannot join
- None.
Trial locations and contacts
1 site in 1 country.
Taiwan1 site, 1 recruiting
- Recruiting
Chang Gung University
Taoyuan, 333
Mei-Ling Cheng, PhD, 886-3-2118800 ext. 3650, chengm@mail.cgu.edu.tw
About this study
With the rapid growth of the global elderly population, the studies of the biomarkers of the sarcopenia and aging are under investigation in different ways. The investigators use Metabolomics to explore the biomarkers of the sarcopenia and aging of the senior adults.
Read the detailed description
Metabolomics is the emerging platform technology to address the complexity of a living system. In translational research, metabolomics approaches may enable the detection of multiple disease risk factors and interactions, disease progression, and response of patients to a particular therapy with or without side effects. Metabolomics may provide comprehensive information and improve diagnosis and prognosis which are particularly promising in human complex degenerative diseases. The investigators use Metabolomics to explore the biomarkers of the sarcopenia and aging of the senior adults.
- Conditions
- Sarcopenia, Aging
- Being tested
- blood and urine sampling
- Keywords
- Sarcopenia, Aging, Biomarkers, Metabolomics
- Medical subject headings
- Sarcopenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
blood and urine samplingDiagnostic test
Ten mL blood and 15mL urine are collected.
What is being measured
The primary outcome is the main question the study is designed to answer.
The biomarkers of the sarcopenia and aging in senior adults.
Metabolomics to explore the biomarkers of the sarcopenia and aging.
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Apr 2017
- Study start6 Mar 2017
- Primary completion15 Mar 2017
- Study completion31 Dec 2017 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for SarcopeniaStudies of the same condition, open and under way.
- More trials run by Chang Gung Memorial HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 650 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Chang Gung Memorial Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Chang Gung University
- Responsible party
- Sponsor
- Investigators
- Chih-Ming Lin, M.D., Study chair, Chang Gung Memorial HospitalMei-Ling Cheng, PhD, Principal investigator, Chang Gung University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03121326
- Sponsor's protocol ID
- 201700245B0
- Status last verified
- Mar 2017
- First submitted
- 17 Apr 2017
- Last updated
- 19 May 2017
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 19 May 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Study of Sarcopenia and Aging Biomarkers by the Metabolomics
- ClinicalTrials.gov ID
- NCT03121326
- Acronym / sponsor ID
- 201700245B0
- Conditions
- Sarcopenia, Aging
- Keywords
- Sarcopenia, Aging, Biomarkers, Metabolomics
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 650 participants (estimated)
- Lead sponsor
- Chang Gung Memorial HospitalUniversity, hospital or other
- Collaborators
- Chang Gung University
- Study start
- 6 Mar 2017 (actual)
- Primary completion
- 15 Mar 2017 (actual)
- Study completion
- 31 Dec 2017 (estimated)
- First posted
- 20 Apr 2017 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
With the rapid growth of the global elderly population, the studies of the biomarkers of the sarcopenia and aging are under investigation in different ways. The investigators use Metabolomics to explore the biomarkers of the sarcopenia and aging of the senior adults.
Detailed description
Metabolomics is the emerging platform technology to address the complexity of a living system. In translational research, metabolomics approaches may enable the detection of multiple disease risk factors and interactions, disease progression, and response of patients to a particular therapy with or without side effects. Metabolomics may provide comprehensive information and improve diagnosis and prognosis which are particularly promising in human complex degenerative diseases. The investigators use Metabolomics to explore the biomarkers of the sarcopenia and aging of the senior adults.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 60 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- 650 residents of the Chang Gung Health and Culture Village aged over 60.
Key inclusion criteria (4 listed)
- residents of the Chang Gung Health and Culture Village
- mostly independent and do not require nursing assistance
- capable of managing their daily living activities
- aged ≧ 60
Key exclusion criteria (1 listed)
- None.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| blood and urine samplingTen mL blood and 15mL urine are collected. | Diagnostic test | – |
Primary outcome
The biomarkers of the sarcopenia and aging in senior adults.
Time frame: one year
Metabolomics to explore the biomarkers of the sarcopenia and aging.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 May 2017.
- Individual participant dataSharing planned: Undecided
Related trials for Sarcopenia
Enrolling by invitation
Online Exercise Program for Transplant Patients: A Pilot Study
Kidney Transplantation, Physical Function
Not yet recruitingPhase 2
A Study of Bimagrumab in Participants With HFpEF
Heart Failure, Diastolic, Diastolic Heart Failure
Not yet recruiting
The Aim of the Study is to Decipher the Alterations in Signalling Pathways of Skeletal Muscle Stem Cells (Satellite Cells (SCs)) in Individuals With COPD, as Well as to Examine the Effect of Exercise Training on SCs.
COPD (Chronic Obstructive Pulmonary Disease), Sarcopenia in Elderly
Not yet recruitingPhase 2
MF-300 for Treatment of Age-Related Sarcopenia
Sarcopenia in Elderly
Not yet recruitingObservational study
Validation of Uzbek SARC-F and IPAQ-SF Questionnaires in Adults With and Without Hypothyroidism
Hypothyroidism, Psychometrics
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Chih-Ming Lin, M.D. study chair
Chang Gung Memorial Hospital
Mei-Ling Cheng, PhD principal investigator
Chang Gung University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Sarcopenia and Aging, run by Chang Gung Memorial Hospital at 1 site in Taiwan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 19 May 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Chih-Ming Lin, M.D. (886-975362603, lin789@adm.cgmh.org.tw), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The biomarkers of the sarcopenia and aging in senior adults. (time frame: one year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2017.